Patent SG-11201909113V-A (SG)
Title: Dna methylation and mutational analysis methods for bladder cancer surveillance
Inventor: LOPATIN MARGARITA
IPC: C12Q1/6886
Filed: 2018-05-17
Abstract: 1 0.2 0.3 OA 0.5 0.6 0.7 0.8 0.9 P091.444oD quantile speciriCitc , 52 .41 ?•i , 77.9% (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIP0 I PCT Hu omit VIII °nolo olotill ommoolio iflo oimIE (10) International Publication Number WO 2018/213550 Al (51) International Patent Classification: C12Q 1/6886 (2018.01) (21) International Application Number: PCT/US2018/033146 (22) International Filing Date: 17 May 2018 (17.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/508,274 18 May 2017 (18.05.2017) US (71) Applicant: GENOMIC HEALTH, INC. [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). (72) Inventors: LOPATIN, Margarita; 301 Penobscot Dri- ve, Redwood City, California 94603 (US). TSIATIS, Athanasios; 301 Penobscot Drive, Redwood City, Califor- nia 94603 (US). SILK, Christopher N.; 301 Penobscot Drive, Redwood City, California 94603 (US). MILLER, David P.; 1080 Peralta Avenue, Albany, California 94706 (US). CRAGER, Michael; 301 Penobscot Drive, Red- wood City, California 94603 (US). FEBBO, Phillip; 301 Penobscot Drive, Redwood City, California 94603 (US). KNEZEVIC, Dej an; 301 Penobscot Drive, Redwood City, California 94603 (US). (74) Agent: DOHERTY, Elizabeth A. et al.; 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: DNA METHYLATION AND MUTATIONAL ANALYSIS METHODS FOR BLADDER CANCER SURVEILLANCE 1.00 099 0.98 0.97 0.96 High Risk Recur t11 1 \"I 1.0 0.8 0.6 0.4 02 99 . 7% 98.8% 0.05 0.0 0.1 0.2 0.3 0.4 0.5 0.8 0.7 0.8 69 0.0 Population qthar669 Sensith.My 1.0 0.6 0.8 0.6 0.6 0.4 0) 0.2 w. a2 04 96.596 0.0 0.0 \" 0.0 0.1 02 0.3 04 0.5 D.6 0.7 0.8 0.9 1.0 popw.ation qumUe 0.0 01 0.2 201 0.4 6.5 OA 0.7 0.6 0.9 1.0 Popti;aton quantilt., Fig. 1 00 (57) : The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for O presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence. C [Continued on next page] WO 2018/213550 Al MIDEDIMOHNIIME1010010ElliOMMINUMEHOIS EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))